Monique N. Dolecki, Investor Relations - 201-847-5378
Kristen Cardillo, Corporate Communications - 201-847-5657
BD ANNOUNCES RESULTS FOR 2019 FIRST FISCAL QUARTER;
REAFFIRMS FISCAL 2019 GUIDANCE
As reported, revenues of $4.160 billion increased 35.1 percent.
On a comparable, currency-neutral basis, revenues increased 5.2 percent.
As reported, diluted earnings per share of $2.05 increased 369.7 percent.
As adjusted, diluted earnings per share of $2.70 increased 8.9 percent, or 14.9 percent on a currency-neutral basis.
The company reaffirms its full fiscal year 2019 revenue and adjusted diluted earnings per share guidance.
Franklin Lakes, NJ (February 5, 2019) - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.160 billion for the first fiscal quarter ended December 31, 2018. This represents an increase of 35.1 percent from the prior-year period, which is primarily due to the acquisition of C. R. Bard. On a comparable, currency-neutral basis, revenues increased 5.2 percent over the prior-year period.
“We are very pleased with our strong start to fiscal year 2019. As noted in our pre-announcement, results were better than expected across all three segments,” said Vincent A. Forlenza, Chairman and CEO. “It is evident that the combination of BD and C. R. Bard is delivering value to customers, patients and shareholders around the world.”
First Quarter Fiscal 2019 Operating Results
As reported, diluted earnings per share for the first quarter were $2.05, compared with $(0.76) in the prior-year period. This represents an increase of 369.7 percent and is primarily due to the gain on the sale of the Advanced Bioprocessing business, and net expense related to U.S. tax reform in the prior-year period. Adjusted diluted earnings per share were $2.70, compared with $2.48 in the prior-year period. This represents an increase in adjusted diluted earnings per share of 8.9 percent, or 14.9 percent on a currency-neutral basis.
The following information was filed by Becton Dickinson Co (BDX) on Tuesday, February 5, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Becton Dickinson Co's financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed, and by Becton Dickinson Co.
Ticker: BDX CIK: 10795 Form Type: 10-Q Quarterly Report Accession Number: 0000010795-19-000009 Submitted to the SEC: Tue Feb 05 2019 8:42:40 AM EST Accepted by the SEC: Tue Feb 05 2019 Period: Monday, December 31, 2018 Industry: Surgical And Medical Instruments And Apparatus